Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease
Different indicators have been proposed to assess GO activity, including short duration of treatment ( 3
KaiserMPereiraSPohlLKetelhutSKemperBGorzelannyCet al
The downside is that you're layering tirzepatide's GIP effects on top of residual semaglutide (both have ~5-day half-lives, so semaglutide is still present for 2-3 weeks after your last dose)
Risks include weight gain, hypoglycemia, pancreatitis, cirrhosis, heart disease, cancer, mental health issues, and an increased likelihood of accidents
56 They cut down on amyloid beta plaques by lowering the activity of BACE1, an enzyme that helps make amyloid beta